NKTR - ネクタ―・セラピュ―ティクス (Nektar Therapeutics)

NKTRのニュース

   Gram-Negative Bacterial Infection Market - Development Assessment 2025 | Nektar Therapeutics, Dainippon Sumitomo Pharma Co., Ltd.  2021/06/18 08:12:39 OpenPR
Global Gram-Negative Bacterial Infection Market: Snapshot Worldwide, antimicrobial resistance is a soaring concern for a range of diseases, especially for enteric fever, respiratory tract infections, and various infections related with gram-negative bacilli (GNB). An upsurge in antibiotic resistance is mainly due
   Natural Killer Cell Therapy Market by Growth Analysis (2020-2026) | Nektar Therapeutics, Innate Pharma SA, Affimed  2021/06/14 10:45:12 Jumbo News
QYResearch Published Global Natural Killer Cell Therapy Market Research Report 2020: Industry Growth, Opportunities, Vendors, Shares, Competitive Strategies And Forecasts 2026. Los Angeles, United State The report on the global Natural Killer Cell Therapy market is a compilation of intelligent, broad research studies that will help players and stakeholders to make informed business decisions in []
   Nano-Medical Device Market 2021 Emerging Trends and Growth Analysis Till 2028 | Affymetrix, Crucell N.V., Flamel Technologies S.A., Nektar Therapeutics, Par Pharmaceutical companies Inc & More  2021/06/12 09:00:00 iCrowdNewswire
Worldwide Nano-Medical Device Market Analysis to 2028 is a specialized and in-depth study of the Nano-Medical Device Market Industry with a focus on the global market trend. The report aims []
   Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 42nd Annual Global Healthcare Conference  2021/06/07 00:00:00 BioSpace
Nektar Therapeutics'' (Nasdaq: NKTR) senior management is scheduled to participate in a virtual fireside chat at the upcoming Goldman Sachs 42 nd Annual Global Healthcare Conference on Tuesday, June 8, 2021 at 2:10 p.m. Eastern Time .
   Bristol-Myers Squibb Company Consensus Indicates Potential 14.7% Upside  2021/05/31 11:09:16 DirectorsTalk
Bristol-Myers Squibb Company with ticker code (BMY) have now 17 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The target price ranges between 90 and 62 calculating the mean target price we have 75.37. Given that the stocks previous close was at 65.71 this now indicates there is a potential upside of 14.7%. There is a 50 day moving average of 65.15 and the 200 moving average now moves to 62.94. The market capitalisation for the company is $146,742m. Find out more information at: /> [stock_market_widget type="chart" symbol="BMY" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis.
   Gram-Negative Bacterial Infection Market - Development Assessment 2025 | Nektar Therapeutics, Dainippon Sumitomo Pharma Co., Ltd.  2021/06/18 08:12:39 OpenPR
Global Gram-Negative Bacterial Infection Market: Snapshot Worldwide, antimicrobial resistance is a soaring concern for a range of diseases, especially for enteric fever, respiratory tract infections, and various infections related with gram-negative bacilli (GNB). An upsurge in antibiotic resistance is mainly due
   Natural Killer Cell Therapy Market by Growth Analysis (2020-2026) | Nektar Therapeutics, Innate Pharma SA, Affimed  2021/06/14 10:45:12 Jumbo News
QYResearch Published Global Natural Killer Cell Therapy Market Research Report 2020: Industry Growth, Opportunities, Vendors, Shares, Competitive Strategies And Forecasts 2026. Los Angeles, United State The report on the global Natural Killer Cell Therapy market is a compilation of intelligent, broad research studies that will help players and stakeholders to make informed business decisions in []
   Nano-Medical Device Market 2021 Emerging Trends and Growth Analysis Till 2028 | Affymetrix, Crucell N.V., Flamel Technologies S.A., Nektar Therapeutics, Par Pharmaceutical companies Inc & More  2021/06/12 09:00:00 iCrowdNewswire
Worldwide Nano-Medical Device Market Analysis to 2028 is a specialized and in-depth study of the Nano-Medical Device Market Industry with a focus on the global market trend. The report aims []
   Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 42nd Annual Global Healthcare Conference  2021/06/07 00:00:00 BioSpace
Nektar Therapeutics'' (Nasdaq: NKTR) senior management is scheduled to participate in a virtual fireside chat at the upcoming Goldman Sachs 42 nd Annual Global Healthcare Conference on Tuesday, June 8, 2021 at 2:10 p.m. Eastern Time .
   Bristol-Myers Squibb Company Consensus Indicates Potential 14.7% Upside  2021/05/31 11:09:16 DirectorsTalk
Bristol-Myers Squibb Company with ticker code (BMY) have now 17 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The target price ranges between 90 and 62 calculating the mean target price we have 75.37. Given that the stocks previous close was at 65.71 this now indicates there is a potential upside of 14.7%. There is a 50 day moving average of 65.15 and the 200 moving average now moves to 62.94. The market capitalisation for the company is $146,742m. Find out more information at: /> [stock_market_widget type="chart" symbol="BMY" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis.
   Gram-Negative Bacterial Infection Market - Development Assessment 2025 | Nektar Therapeutics, Dainippon Sumitomo Pharma Co., Ltd.  2021/06/18 08:12:39 OpenPR
Global Gram-Negative Bacterial Infection Market: Snapshot Worldwide, antimicrobial resistance is a soaring concern for a range of diseases, especially for enteric fever, respiratory tract infections, and various infections related with gram-negative bacilli (GNB). An upsurge in antibiotic resistance is mainly due
   Natural Killer Cell Therapy Market by Growth Analysis (2020-2026) | Nektar Therapeutics, Innate Pharma SA, Affimed  2021/06/14 10:45:12 Jumbo News
QYResearch Published Global Natural Killer Cell Therapy Market Research Report 2020: Industry Growth, Opportunities, Vendors, Shares, Competitive Strategies And Forecasts 2026. Los Angeles, United State The report on the global Natural Killer Cell Therapy market is a compilation of intelligent, broad research studies that will help players and stakeholders to make informed business decisions in []
   Nano-Medical Device Market 2021 Emerging Trends and Growth Analysis Till 2028 | Affymetrix, Crucell N.V., Flamel Technologies S.A., Nektar Therapeutics, Par Pharmaceutical companies Inc & More  2021/06/12 09:00:00 iCrowdNewswire
Worldwide Nano-Medical Device Market Analysis to 2028 is a specialized and in-depth study of the Nano-Medical Device Market Industry with a focus on the global market trend. The report aims []
   Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 42nd Annual Global Healthcare Conference  2021/06/07 00:00:00 BioSpace
Nektar Therapeutics'' (Nasdaq: NKTR) senior management is scheduled to participate in a virtual fireside chat at the upcoming Goldman Sachs 42 nd Annual Global Healthcare Conference on Tuesday, June 8, 2021 at 2:10 p.m. Eastern Time .
   Bristol-Myers Squibb Company Consensus Indicates Potential 14.7% Upside  2021/05/31 11:09:16 DirectorsTalk
Bristol-Myers Squibb Company with ticker code (BMY) have now 17 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The target price ranges between 90 and 62 calculating the mean target price we have 75.37. Given that the stocks previous close was at 65.71 this now indicates there is a potential upside of 14.7%. There is a 50 day moving average of 65.15 and the 200 moving average now moves to 62.94. The market capitalisation for the company is $146,742m. Find out more information at: /> [stock_market_widget type="chart" symbol="BMY" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis.

calendar